Combined pergolide-associated valvular heart disease (PAVHD) and Achilles tendon contractures

William D. Freeman, Peter T. Dorsher, Robert E. Safford, Jay Van Gerpen, William D. Edwards

Abstract


A Letter to Editor

Full Text:

PDF

References


Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol. 2007;6(9):826-9.

Hu MT, Bland J, Clough C, Ellis CM, Chaudhuri KR. Limb contractures in levodopa-responsive parkinsonism: a clinical and investigational study of seven new cases. J Neurol. 1999;246(8):671-6.

Charcot JM. Lectures on the diseases of the nervous system (paralysis agitans), lecture V. London: New Sydenham Society; 1877. p. 140-7.

Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, et al. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in

cardiac valvular fibrosis. Clin Neuropharmacol. 2006;29(2):80-6.

Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007;356(1):39-46.

Fukae J, Tanaka S, Hattori N. Retroperitoneal fibrosis secondary to pergolide therapy. Intern Med. 2010;49(15):1687.


Refbacks

  • There are currently no refbacks.


2016 Department of Medical Sciences, Academy of Sciences and Arts of Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina. All rights reserved.
 
The full text of articles published in this journal can be used free of charge for personal and educational purposes while respecting authors and publishers’ copyrights. For commercial purposes no part of this journal may be reproduced without the written permission of the publisher.